In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Coup for Gen-Probe

Executive Summary

Chiron and Gen-Probe have entered into a strategic alliance which gives Chiron access to Gen-Probe's nucleic acid technologies and Gen-Probe gets rights to use HCV and other proprietary Chiron technology in manufacturing assays. Chiron will be selling Gen-Probe instruments to blood banks and clinical labs. Blood banks are starting to get interested in DNA screening for some major viral infections like HIV and HCV, because the technique is more sensitive and specific. The deal is a coup for Gen-Probe, because it gets rights to one of most coveted patents in diagnostics and it broadens Chiron's DNA platform beyond the disappointing bDNA.

You may also be interested in...



Thermo Fisher Scientific, Hillrom To Acquire Diagnostics Companies To Bolster Portfolios

Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.

Cosmetic And Personal Care Trademark Review 19 January, 2021

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CMS Extends National Medicare Coverage For Transcatheter Mitral Valve Repair

Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel